The pathologic substrate of the clinical syndrome of dementia with Lewy bodies (DLB) remains to be determined. Only a few prospective clinicopathologic studies have been reported. In those reports, most cases of DLB had neocortical or limbic Lewy bodies and Alzheimer-type pathology below threshold for diagnosis of Alzheimer's disease. These results are in accord with recent retrospective clinicopathologic studies of dementia occurring in Parkinson's disease, in which cortical Lewy bodies, rather than concurrent Alzheimer's disease, are increasingly recognized as the pathologic substrate of dementia. Additional clinicopathologic studies are warranted to address the role of other Lewy-related pathology, most notably Lewy neurites, in the cognitive impairment of DLB. (J Geriatr Psychiatry Neurol 2002; 15:000–000).
Get full access to this article
View all access options for this article.
References
1.
1. Perry RH, McKeith IG, Perry EK, eds., Dementia with Lewy bodies. Cambridge UK: University Press, 1996.
2.
2. McKeith IG, Galasko D, Kosaka K, et al., Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47: 1113–1124.
3.
3. McKeith IG., Clinical Lewy body syndromes. Ann N Y Acad Sci2000; 920: 1–8.
4.
4. Pollanen MS, Dickson DW, Bergeron C., Pathology and biology of the Lewy body. J Neuropathol Exp Neurol1993; 52: 183–191.
5.
5. Dickson DW, Ruan D, Crystal H, et al., Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLBD. Neurology1991; 41: 1402–1409.
6.
6. Dickson DW, Schmidt ML, Lee VM-Y, et al., Hippocampal neurites in diffuse Lewy body disease: immunocytochemical characterization and local origin. Acta Neuropathol (Berl)1994; 87: 269–276.
7.
7. Churchyard A, Lees AJ., The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology1997; 49: 1570–1576.
8.
8. Forno LS., The Lewy body in Parkinson's disease. In: Yahr MD, Bergmann KJ, eds., Parkinson's disease. New York: Raven Press, 1986: 35–43.
9.
9. Iwatsubo T, Yamaguchi H, Fujimuro M, et al., Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol1996; 148: 1517–1529.
10.
10. Goldman JE, Yen S-H, Chiu F-C, Peress NS., Lewy bodies of Parkinson's disease contain neurofilament antigens. Science1983; 221: 1082–1084.
11.
11. Hill WD, Lee VM, Hurtig HI, et al., Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol1991; 309: 150–160.
12.
12. Kuzuhara S, Mori H, Izumiyama N, et al., Lewy bodies are ubiquitinated: a light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl)1988; 75: 345–353.
13.
13. Lennox G, Lowe J, Morrell K, et al., Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry1989; 52: 67–71.
14.
14. Spillantini MG, Schmidt ML, Lee VM, et al., Alpha-synuclein in Lewy bodies. Nature1997; 388: 839–840.
15.
15. Wakabayashi K, Matsumoto K, Takayama K, et al., NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett1997; 239: 45–48.
16.
16. Irizarry MC, Growdon W, Gomez-Isla T, et al., Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol1998; 57: 334–337.
17.
17. Polymeropoulos M, Lavedan C, Leroy E, et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science1997; 276: 2045–2047.
18.
18. Conway KA, Harper JD, Lansbury PT., Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med1998; 4: 1318–1320.
19.
19. Dickson DW., α-Synuclein and the Lewy body disorders. Curr Opin Neurol2001; 14: 423–432.
20.
20. Braak H, Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl)1991; 82: 239–259.
21.
21. Grober E, Dickson D, Sliwinski MJ, et al., Memory and mental status correlates of modified Braak staging. Neurobiol Aging1999; 20: 573–579.
23. Crystal HA, Dickson DW, Sliwinski M, et al., Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol1993; 34: 566–573.
24.
24. Katzman R, Terry RD, DeTeresa R, et al., Clinical, pathological and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol1988; 23: 138–144.
25.
25. Dickson DW, Crystal HA, Mattiace LA, et al., Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging1992; 13: 1–11.
26.
26. Mirra SS, Heyman A, McKeel D, et al., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology1991; 41: 479–486.
27.
27. Hyman BT, Trojanowski JQ., Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol1997; 56: 1095–1097.
28.
28. Lippa CF, Ozawa K, Mann DM, et al., Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol1999; 56: 1111–1118.
29.
29. Dickson DW, Crystal H, Mattiace L, et al., Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl)1989; 78: 572–578.
30.
30. Kosaka K, Yoshimura M, Ikeda K, Budka H., Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree–a new disease?Clin Neuropathol1984; 3: 185–192.
31.
31. McKeith IG, Ballard CG, Perry RH, et al., Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology2000; 54: 1050–1058.
32.
32. McRitchie DA, Reid WG, Halliday GM, et al., Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. J Clin Neurosci1999; 6: 149–154.
33.
33. Ballard C, O'Brien J, Gray A, et al., Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol2001; 58: 977–982.
34.
34. Mega MS, Masterman DL, Benson DF, et al., Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology1996; 47: 1403–1409.
35.
35. Litvan I, MacIntyre A, Goetz CG, et al., Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol1998; 55: 969–978.
36.
36. Verghese J, Crystal HA, Dickson DW, Lipton RB., Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology1999; 53: 1974–1982.
37.
37. Luis CA, Barker WW, Gajaraj K, et al., Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry1999; 14: 526–533.
38.
38. Hohl U, Tiraboschi P, Hansen LA, et al., Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol2000; 57: 347–351.
39.
39. Gomez-Tortosa E, Newell K, Irizarry MC, et al., Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology1999; 53: 1284–1291.
40.
40. Rezaie P, Cairns NJ, Chadwick A, Lantos PL., Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett1996; 212: 111–114.
41.
41. Schmidt ML, Martin JA, Lee VM, Trojanowski JQ., Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol (Berl)1996; 91: 475–481.
42.
42. Hamilton RL., Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol2000; 10: 378–384.
43.
43. Marui W, Iseki E, Ueda K, Kosaka K., Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. J Neurol Sci2000; 174: 81–84.
44.
44. Iseki E, Marui W, Kosaka K, Ueda K., Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett1999; 265: 9–12.
45.
45. Hughes AJ, Daniel SE, Blankson S, Lees AJ., A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol1993; 50: 140–148.
46.
46. Mayeux R, Stern YA, Rosenstein R, et al., An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol1988; 45: 260–262.
47.
47. Jellinger KA., Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl1997; 51: 57–82.
48.
48. Mindham RHS, Biggins CA, Boyd JL, et al., A controlled study of dementia in Parkinson's disease over 54 months. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds., Parkinson's disease: from basic research to treatment. New York: Raven Press, 1990: 470–474.
49.
49. Cummings JL., The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer's type. Eur Neurol1988; 28(Suppl 1), 15–23.
50.
50. Connor DJ, Salmon DP, Sandy TJ, et al., Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol1998; 55: 994–1000.
51.
51. Ball MJ., The morphological basis of dementia in Parkinson's disease. Can J Neurol Sci1984; 11(Suppl), 180–184.
52.
52. Chiu HC, Mortimer JA, Slager U, et al., Pathologic correlates of dementia in Parkinson's disease. Arch Neurol1986; 43: 991–995.
53.
53. Gaspar P, Gray F., Dementia in idiopathic Parkinson's disease: a neuropathological study of 32 cases. Acta Neuropathol (Berl)1984; 64: 43–52.
54.
54. Hakim AM, Mathieson G., Dementia in Parkinson's disease: a neuropathologic study. Neurology1979; 29: 1209–1214.
55.
55. Yoshimura M., Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. Eur Neurol1988; 28(Suppl 1), 29–35.
56.
56. Mattila PM, Roytta M, Torikka H, et al., Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl)1998; 95: 576–582.
57.
57. Hurtig HI, Trojanowski JQ, Galvin J, et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology2000; 54: 1916–1921.
58.
58. Apaydin H, Ahlskog JE, Parisi JE, et al., Parkinson's disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2001; 102–112.
59.
59. Dickson DW, Davies P, Mayeux R, et al., Diffuse Lewy body disease: neuropathological and biochemical studies of six patients. Acta Neuropathol (Berl)1987; 75: 8–15.
60.
60. Hansen L, Salmon D, Galasko D, et al., Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology1990; 40: 1–8.
61.
61. Perry EK, Marshall E, Perry RH, et al., Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Dis1990; 4: 87–95.
62.
62. Samuel W, Caligiuri M, Galasko D, et al., Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry2000; 15: 794–802.
63.
63. Zweig RM, Cardillo JE, Cohen M, et al., The locus ceruleus and dementia in Parkinson's disease. Neurology1993; 43: 986–989.
64.
64. D'Amato RJ, Zweig RM, Whitehouse PJ, et al., Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol1987; 22: 229–236.
65.
65. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK., Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol1989; 26: 47–50.
66.
66. Lennox G, Lowe J, Landon M, et al., Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry1989; 52: 1236–1247.
